New Parkinson's drug candidate enters early human testing

NCT ID NCT07422675

First seen Feb 21, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This early-stage study tests a single dose of SER-252 in 40 people with Parkinson's disease who experience motor fluctuations (uncontrolled movements). The main goal is to check the drug's safety and how the body processes it. Participants receive either SER-252 or a placebo, and researchers monitor side effects and drug levels over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CMAX

    RECRUITING

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • K2 Medical Research LLC

    RECRUITING

    Maitland, Florida, 32751, United States

    Contact

  • Monash

    RECRUITING

    Melbourne, Victoria, 3170, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Quest Research Institute

    RECRUITING

    Farmington Hills, Michigan, 28555, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rocky Mountain Clinical Research

    NOT_YET_RECRUITING

    Englewood, Colorado, 80113, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Velocity Clinical Research

    NOT_YET_RECRUITING

    Hallandale, Florida, 33009, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.